# US 2015/0174266 A1 · Aprotinin polypeptides for transporting a compound across the blood-brain barrier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174266 A1
- Document ID: US20150174266A1
- Status: Published application
- Kind: A1
- Application number: 14/457,861
- Filed: 2014-08-12
- Published: 2015-06-25
- Earliest claimed: 2005-02-18
- Assignees: Angiochem Inc.
- Applicants: Angiochem Inc.
- Inventors: Richard Beliveau; Michel Demeule; Christian Che; Anthony Regina
- Web page: https://patentgrep.com/patent/US20150174266A1

## CPC

- A61K 39/44: Antibodies bound to carriers
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/10: for petit-mal
- A61P 25/12: for grand-mal
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/8117: {Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- Y10S 977/915: Therapeutic or pharmaceutical composition
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptides for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases.

## Claims

### Claim 1

A method for treating a mammal having a neurological disease, said method comprising administering to said mammal a conjugate comprising:
(a) a polypeptide comprising an amino acid sequence having at least 80% identity to the sequence of Angiopep-1 (SEQ ID NO:67), wherein said polypeptide has a substitution at the position corresponding to the cysteine at position 7 of the Angiopep-1 sequence; and
(b) an agent for treating said neurological disease, wherein said agent is conjugated to said polypeptide,
wherein said conjugate is capable of crossing the blood-brain barrier or an in vitro model thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said neurological disease is selected from the group consisting of a brain cancer, a brain metastasis, schizophrenia, epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, and obesity.

### Claim 3 (depends on 2)

The method of claim 2, wherein said brain cancer is a glioma.

### Claim 4 (depends on 3)

The method of claim 3, wherein said glioma is a glioblastoma.

### Claim 5 (depends on 1)

The method of claim 1, wherein said percent identity is at least 85%.

### Claim 6 (depends on 5)

The method of claim 5, wherein said percent identity is at least 90%.

### Claim 7 (depends on 1)

The method of claim 1, wherein said substitution is a serine substitution.

### Claim 8 (depends on 7)

The method of claim 7, wherein said polypeptide comprises the amino acid sequence of Angiopep-2 (SEQ ID NO:97).

### Claim 9 (depends on 7)

The method of claim 7, wherein said polypeptide consists of the amino acid sequence of Angiopep-2 (SEQ ID NO:97).

### Claim 10 (depends on 1)

The method of claim 1, wherein said agent is an anticancer drug.

### Claim 11 (depends on 10)

The method of claim 10, wherein said anticancer drug is selected from the group consisting of paclitaxel, vinblastine, vincristine, etoposide, doxorubicin, cyclophosphamide, taxotere, melphalan, and chlorambucil, or a combination thereof

### Claim 12 (depends on 11)

The method of claim 11, wherein said anticancer drug is paclitaxel.

### Claim 13 (depends on 11)

The method of claim 11, wherein said anticancer drug is etoposide.

### Claim 14 (depends on 11)

The method of claim 11, wherein said anticancer drug is doxorubicin.

### Claim 15 (depends on 1)

The method of claim 1, wherein said agent is a small molecule drug, an antibiotic, a cellular toxin, an anti-angiogenic compound, or a polypeptide.

### Claim 16 (depends on 15)

The method of claim 15, wherein said agent is a chemotherapeutic agent.

### Claim 17 (depends on 15)

The method of claim 15, wherein said polypeptide is an enzyme.

### Claim 18 (depends on 15)

The method of claim 15, wherein said anti-angiogenic compound is endostatin, catechins, chemokine IP-10, an inhibitor of matrix metalloproteinase, anastellin, vironectin, antithrombin, a tyroskinctyrosine kinase inhibitor, or a VEGF inhibitor.

### Claim 19 (depends on 1)

The method of claim 1, wherein said administration is intra-arterial, intra-nasal, intra-peritoneal, intravenous, intramuscular, subcutaneous, transdermal, or per os.

### Claim at position 20

20-45. (canceled)
